Skip to main content

Table 2 Summary of major clinical events registered after hospital discharge in both patient groups over the 5-year follow-up

From: Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial

  EPO
(n = 68)
Placebo
(n = 70)
 
Death; n(%) 8 (11.8) 6 (8.6) p = 0.53
MI; n(%) 4 (5.9) 2 (2.9) p = 0.38
Death or MI; n(%) 10 (14.7) 7 (10.0) p = 0.40
Stroke; n(%) 1 (1.5) 0 (0) p = 0.31
Death or MI or Stroke; n(%) 10 (14.7) 7 (10.0) p = 0.40
Coronary bypass surgery; n(%) 1 (1.5) 0 (0) p = 0.31
Target lession revascularization; n(%) 15 (22.1) 9 (12.9) p = 0.15
MACE; n(%) 17 (25.0) 12 (17.1) p = 0.26